Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nOPV2 and bOPV in healthy infants
NCT05166031Phase 3Withdrawn
- Sponsor
- Fighting Infectious Diseases in Emerging Countries
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised trial of nOPV2 in poliomyelitis (3 arms), sponsored by Fighting Infectious Diseases in Emerging Countries. Primary endpoints: Seroconversion rate at 2 months and Incidence of serious adverse reactions, important medical reactions and severe solicited adverse reactions at 6 months. Planned start Dec 2020; status: withdrawn.
02
Drugs
nOPV2
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT05166031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166031.